Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm Metastasis × Crizotinib × Clear all

Phase

Phase 1 4 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 5 Multiple Myeloma 4 Lymphoma 3 Lymphoma, Large-Cell, Anaplastic 2 Hematologic Neoplasms 2 Adenocarcinoma 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma, Alveolar 1 Relapsed Pediatric Solid Tumor 1 Rare Tumor 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Lung Adenocarcinoma Metastatic 1 Granuloma, Plasma Cell 1 Gallbladder Neoplasms 1 Endometrial Cancer Recurrent 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Adenocarcinoma of Lung 1

Interventions

Oxaliplatin 55 Capecitabine 53 Fluorouracil 50 Bevacizumab 48 Gemcitabine 44 Leucovorin 42 Paclitaxel 39 Carboplatin 34 Nivolumab 32 Irinotecan 32 pembrolizumab 31 Docetaxel 31 Cisplatin 29 Cetuximab 29 Trastuzumab 21 Radiosurgery 20 Sunitinib 19 Cyclophosphamide 19 Panitumumab 17 Doxorubicin 17 Radiotherapy 15 Pemetrexed 15 Fulvestrant 15 Drug Therapy 15 Interleukin-2 14 Everolimus 14 atezolizumab 13 Sorafenib 13 Ipilimumab 13 Albumin-Bound Paclitaxel 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡